U.S. stock market midday update: Apollomics up 16.31%

U.S. Stock Market Midday Update Apollomics rose 16.31%. According to recent important news: On October 15, Apollomics announced its continued listing on NASDAQ, as the hearing was canceled, allowing the securities to continue trading on NASDAQ. This news alleviated market concerns about the company's delisting, driving the stock price up. On October 14, Apollomics secured additional funding and changed its leadership, reversing the previously planned liquidation decision. This move boosted investor confidence and facilitated the rise in stock price. On October 13, Apollomics released its latest operational update, providing key information about the company's current status, further enhancing market confidence. The NASDAQ market is active, and volatility risks should be monitored. Stocks with High Trading Volume in the Industry Praxis Precision Medicines rose 212.73%. According to recent important news: On October 16, Praxis Precision Medicines announced that its experimental drug ulixacaltamide for movement disorders helped patients improve daily functioning in two late-stage trials, causing the stock price to soar more than twofold in pre-market trading. The drug targets a neurological condition known as essential tremor, for which there is currently no specific approved treatment; On October 16, Praxis Precision Medicines reported positive top-line results from the Phase III trial of ulixacaltamide in the Essential3 project, showing statistical significance across all key secondary endpoints, further driving the stock price up; On October 16, analysts rated Praxis Precision Medicines as a strong buy, with a target price of $191.50, representing a 20.98% upside potential, while Guggenheim maintained a buy rating with a target price of $350.00. The biopharmaceutical industry has performed strongly recently, with significant capital inflows. Recursion Pharmaceuticals fell 3.80%. According to recent important news: On October 16, Recursion Pharmaceuticals became the only biotechnology company to attract investment from AI giant Nvidia. This news drew market attention but failed to prevent the stock price from declining, as investors remain cautious about the long-term success of its AI drug discovery and development methods. Recently, the market has shown interest in the potential of Recursion Pharmaceuticals' AI drug discovery and development methods, although its innovativeness has sparked interest, it has not led to a rise in stock price in the short term There are no other significant news recently. The biotechnology industry is highly volatile and requires cautious attention. AbbVie rose by 0.31%. According to recent important news: On October 13, the FDA expanded the approval of AbbVie's Rinvoq for the treatment of moderate to severe ulcerative colitis and Crohn's disease. This approval broadens the scope of Rinvoq's application and may enhance the company's competitiveness in the relevant market. On October 13, AbbVie's application for TrenibotE injectable botulinum toxin type E was accepted. This product has shown rapid onset and good safety in clinical trials, which may drive the company's growth in the beauty market. On October 15, Enveric Biosciences threatened legal action against AbbVie, accusing its depression candidate drug bretisilocin of patent infringement. This legal dispute may negatively impact the company's reputation and stock price. The pharmaceutical industry is active in innovation, and market volatility risks should be monitored. Stocks ranked among the top in industry market capitalization Biodexa Pharmaceuticals rose by 3.58%, with a market capitalization reaching $52.04 billion, and there is no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, this stock shows significant volatility, and the specific reasons need further observation